Ai-designed Virus Given to a Person in Unprecedented First Trial
WHO:
Yahoo - Radical Numerics, a California AI research lab, said it designed the phages with its AI model Omnii-1.
The Register - Radical Numerics is a San Francisco-based AI lab developing AI models for bioscience.
Yahoo; The Register - The patient had an antibiotic-resistant bacterial infection and few remaining medical options; the patient’s identity and specific infection were not disclosed.
Yahoo; The Register - Bacteriophages are viruses that infect bacteria and can target particular bacterial strains or species.
WHAT:
The Register - Radical Numerics said the treatment moves AI-designed biology from computational predictions and laboratory validation to clinical administration.
Yahoo - Radical Numerics described the milestone as “an early step toward translating AI-guided genome design into personalised therapies.”
The Register - Radical Numerics said its experiments characterize designed phage variants’ activity against target hosts and inform later rounds of modeling and design.
Yahoo; The Register - Radical Numerics said an Omnii-1-designed phage treatment was administered to a human patient for the first time under a physician-led compassionate-use pathway.
The Register - The administered investigational treatment was a cocktail containing AI-designed phage variants.
The Register - Radical Numerics said the cocktail eliminated the patient’s antibiotic-resistant bacterial isolate in laboratory testing before it was administered.
Yahoo; The Register - The company did not disclose the patient’s clinical outcome. It said a single-patient observation does not establish that the therapy is generally safe or effective.
Yahoo - The company said the announcement was pending scientific scrutiny in a peer-reviewed study.
The Register - Omnii-1 was publicly unveiled in the same week as the announcement.
Yahoo - Drug-resistant superbugs are projected to cause nearly 40 million deaths by 2050.
The Register - Stanford University and the Arc Institute previously developed AI-designed phages targeting E. coli; some variants outperformed their natural predecessor in laboratory tests.
WHERE:
Yahoo; The Register - The phage variants were tested against bacteria isolated from the patient’s infection; the isolate was eliminated in vitro.
The Register - The article does not identify where the patient was treated.
The Register - The research discussed Omnii-1’s predictions for phages that could infect Pseudomonas aeruginosa, but did not say the patient had that infection.
WHY:
Yahoo; The Register - The treatment was intended to address antibiotic-resistant bacteria and explore personalized alternatives as antibiotics become ineffective against some infections.
Yahoo; The Register - Phages’ specificity may spare beneficial gut bacteria that broad-spectrum antibiotics can affect.
HOW:
Yahoo - Radical Numerics said its AI could identify and design candidate phages for specific therapeutic requirements.
Yahoo - The startup said current phage-treatment approaches can require a time-consuming search through large environmental collections of phages to find a match for a patient’s infection.
Yahoo - Clinicians begin by extracting a sample of the bacteria causing the infection, then researchers seek or design phages that can kill it.
Yahoo - Radical Numerics said Omnii-1 was trained on diverse genomic sequences, phage genomes, and previously measured phage-host interactions.
Yahoo - The company said it synthesizes designed phage variants and measures their recovery and activity across bacterial strains; recovery indicates whether a designed viral genome can replicate in a laboratory.
Yahoo - Phages bind to specific receptor molecules on target bacteria, enter bacterial cells, replicate, and break the cells open.
The Register - Radical Numerics said Omnii-1 performed competitively against a specialized model at predicting phage-host interactions.
(UPDATED October 23, 2026 19:09 UTC)
A California AI lab says it has designed bacteriophages that were used in a human patient for the first time, in an effort to treat an antibiotic-resistant infection. The physician-led treatment used a cocktail of phage variants created by Radical Numerics’ model, Omnii-1. The viruses target bacteria, and tests in the lab showed the cocktail eliminated bacteria isolated from the patient’s infection. The patient’s identity, specific infection and clinical outcome have not been disclosed. The company cautions that one patient’s treatment cannot show whether the therapy is generally safe or effective, and says the work is awaiting peer review. Omnii-1 was trained on genomic data and information about interactions between phages and bacteria, helping identify candidates for specific infections. Unlike broad-spectrum antibiotics, phages may spare beneficial bacteria, but finding a match can take time. The company calls this an early step toward personalized therapies, not established treatment.
--
(UPDATED October 23, 2026 17:26 UTC)
A California AI lab says a treatment built with its model has been given to a human patient for the first time. Radical Numerics designed a cocktail of bacteriophages, viruses that infect bacteria, using its Omnii-1 model, then tested the variants against bacteria isolated from the patient. The company said the cocktail eliminated that isolate in laboratory tests before treatment. The patient had an antibiotic-resistant infection and few remaining options, but the infection and the patient’s identity were not disclosed. The clinical outcome is also unknown, and the company cautions that one case cannot establish safety or effectiveness. Phages can target particular bacteria, potentially sparing beneficial gut microbes affected by broad-spectrum antibiotics. Omnii-1 was trained on genomic data and measured phage-host interactions, and the company says laboratory results guide further design. Radical Numerics calls the treatment an early step toward personalized therapies; its announcement is still awaiting peer review.
--
(UPDATED October 23, 2026 16:24 UTC)
A California AI lab says it has used a treatment designed by its model to target an antibiotic-resistant infection in a human for the first time. The physician-led treatment involved compassionate use, after other medical options had dwindled. Radical Numerics, a San Francisco-based bioscience lab, designed a cocktail of bacteriophages with its model, Omnii-1. Phages are viruses that infect bacteria, often targeting particular strains while potentially sparing beneficial gut bacteria. Before treatment, the lab said the cocktail eliminated bacteria isolated from the patient’s infection in laboratory tests. The patient’s identity, specific infection, and clinical outcome have not been disclosed. The company cautioned that one case cannot establish the treatment’s safety or effectiveness, and said the announcement awaits peer-reviewed scrutiny. Omnii-1 was trained on genomic data and phage-host interactions, as researchers seek personalized approaches to infections that no longer respond to antibiotics.